Realizing the curative power of alpha radiopharmaceuticals for mainstream cancer care
Radiopharmaceuticals transformed
Delivering targeted alpha-emitting drugs with precision pharmacology
Aktis Oncology is committed to transforming cancer care with novel platform technologies that will enable us to design and develop powerful precision radiopharmaceuticals. These are targeted therapies that safely harness the superior anticancer potency of alpha-emitting particles. Working on a broad set of targets present in commonly occurring cancers, Aktis molecules are poised to revolutionize cancer treatment and impact tumors with currently limited treatment options.
Our Science
Aktis Oncology is committed to transforming cancer care with novel platform technologies that will enable us to design and develop powerful precision radiopharmaceuticals. These are targeted therapies that safely harness the superior anticancer potency of alpha-emitting particles. Working on a broad set of targets present in commonly occurring cancers, Aktis molecules are poised to revolutionize cancer treatment and impact tumors with currently limited treatment options.
Aktis Oncology is committed to transforming cancer care with novel platform technologies that will enable us to design and develop powerful precision radiopharmaceuticals. These are targeted therapies that safely harness the superior anticancer potency of alpha-emitting particles. Working on a broad set of targets present in commonly occurring cancers, Aktis molecules are poised to revolutionize cancer treatment and impact tumors with currently limited treatment options.
Join us
Join a team dedicated to discovering and developing transformative therapies that put solid cancers into remission. View Careers
